X. Filella et al., CYTOKINES (IL-6,TNF-ALPHA,IL-1-ALPHA) AND SOLUBLE INTERLEUKIN-2 RECEPTOR AS SERUM TUMOR-MARKERS IN MULTIPLE-MYELOMA, Cancer detection and prevention, 20(1), 1996, pp. 52-56
The serum levels of interleukin-6 (IL-6), tumor necrosis factor-alpha
(TNF-alpha), soluble interleukin-2 receptor (sIL-2r), and interleukin-
1 alpha (IL-1 alpha) were measured in 30 healthy subjects, 22 patients
with monoclonal gammopathy of undetermined significance (MGUS), five
patients with smoldering multiple myeloma (SMM), and 46 with multiple
myeloma (MM). Serum levels of IL-6, TNF-alpha, and sIL-2r were signifi
cantly increased in patients with active MM when compared with normal
controls. Furthermore, MM patients with advanced aggressive disease ha
d significantly higher levels of IL-6, TNF-alpha, and sIL-2r than thos
e with MM in plateau phase. In conclusion, our data support the involv
ement of IL-6, TNF-alpha, and sIL-2r in MM. This confirms recent in vi
tro studies suggesting that these cytokines may play a central role in
the pathogenesis of MM. Our data also show that serum levels of TNF-a
lpha, sIL-2r, and, particularly, IL-6 could be useful in the clinical
management of patients with MM.